Improving access and affordability could be transformative for public health, given that about 88% of Americans are ...

Obesity costs U.S. health care nearly $173 billion yearly. With more than 200 related complications such as heart disease, ...

In this week’s edition of InnovationRx, we look at the health impact of the Republican spending bill, a startup that built a hospital in India to test its AI software, the impact of the vaccine panel ...

Since President Trump was sworn into office for a second term, he has proposed or initiated changes impacting Medicare.

Insulin changed the way we treat and manage diabetes. Chemotherapy has precipitously reduced the mortality rate of certain ...

Americans with obesity face almost double the financial hardship as their peers without obesity, according to a study published in Annals of Internal Medicine that highlighted not only elevated out-of ...

Policymakers must prioritize access to innovative obesity care in tackling the obesity epidemic across the United States.

Pennsylvania Governor Josh Shapiro's office has said it is looking to change eligibility for weight loss drugs as part of its ...

Medicare Part D coverage of obesity medications could lead to a large increase in health care costs due to the prices of the drugs, according to data from a microsimulation model published in JAMA ...

A decision by CMS to not move forward with a proposed rule allowing obesity medications to be covered under Medicare Part D has several medical societies advocating for change. As Healio ...

The conversation moves fast. Keep up with the Prompt newsletter. Too bad the Centers for Medicare and Medicaid Services decided on Friday not to broadly cover new anti-obesity medications.

The Biden administration’s rule would have expanded access to obesity drugs, including pricey GLP-1 drugs, to an estimated 3.4 million people on Medicare and 4 million people in Medicaid.